Victor A Levin
Overview
Explore the profile of Victor A Levin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Levin V, Chan J, Datta M, Yee J, Jain R
J Neurooncol
. 2017 Jun;
134(2):325-330.
PMID: 28631191
Given prior studies that suggest the use of angiotensin system inhibitors (ASIs) is associated with prolonged overall survival (OS) in glioblastoma (GBM) patients, we evaluated the effect of ASIs in...
12.
13.
Levin V, Tonge P, Gallo J, Birtwistle M, Dar A, Iavarone A, et al.
Neuro Oncol
. 2015 Sep;
17 Suppl 6:vi1-26.
PMID: 26403167
Following the first CNS Anticancer Drug Discovery and Development Conference, the speakers from the first 4 sessions and organizers of the conference created this White Paper hoping to stimulate more...
14.
Levin V
Oncology (Williston Park)
. 2015 May;
29(4):264, 266-8.
PMID: 25952490
No abstract available.
15.
Levin V, Mendelssohn N, Chan J, Stovall M, Peak S, Yee J, et al.
J Neurooncol
. 2015 Jan;
122(1):145-50.
PMID: 25575937
Bevacizumab (BEV, Avastin(®)) produces durable objective radiological responses of 20-26 %, median response durations of 16-18 weeks, and median overall survival (mOS) of 31-40 weeks. While the use of BEV...
16.
Penas-Prado M, Hess K, Fisch M, Lagrone L, Groves M, Levin V, et al.
Neuro Oncol
. 2014 Sep;
17(2):266-73.
PMID: 25239666
Background: Chemoradiation, followed by adjuvant temozolomide, is the standard treatment for newly diagnosed glioblastoma. Adding other active agents may enhance treatment efficacy. Methods: The primary objective of this factorial phase...
17.
Hess K, Levin V
Clin Cancer Res
. 2014 Feb;
20(6):1404-9.
PMID: 24501392
Information about the survival experience for a group of patients is almost exclusively conveyed using plots of the survival function. However, the hazard function provides information about the survival experience...
18.
19.
Lee E, Kuhn J, Lamborn K, Abrey L, DeAngelis L, Lieberman F, et al.
Neuro Oncol
. 2012 Oct;
14(12):1511-8.
PMID: 23099651
The activity of single-agent targeted molecular therapies in glioblastoma has been limited to date. The North American Brain Tumor Consortium examined the safety, pharmacokinetics, and efficacy of combination therapy with...
20.
Levin V, Panchabhai S, Shen L, Baggerly K
Proteome Sci
. 2012 Jan;
10(1):5.
PMID: 22276931
Background: Three dimensional (3D) growths of cancer cells in vitro are more reflective of in situ cancer cell growth than growth in monolayer (2D). The present study is designed to...